{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T15:17:35Z","timestamp":1769267855206,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2018-11648"],"award-info":[{"award-number":["2018-11648"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) patients often experience relapse or progression after treatment, emphasizing the need for better prognostic markers. This study investigated baseline FDG uptake and volume of healthy tissues and tumours, to assess their association with time-to-progression (TTP) in DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 259 newly diagnosed DLBCL patients. Outcome was two-year TTP after treatment initiation. Automatic segmentation of tissues was performed on the low dose CT scans. Tumour lesions were outlined with a semi-automated segmentation method (standardised uptake value\u2009\u2265\u20094) and subtracted from the tissues. Mean standardised uptake value (SUVmean), tissue-to-blood SUVmean ratio, volume, and total lesion glycolysis (TLG) were determined for the spleen, liver, kidneys, lungs, and brain. Only SUVmean and SUVmean ratio were assessed for fat, bone, and skeletal muscle. Intercorrelations among all tissues and correlations with tumour TLG were calculated. Volume and uptake measures were compared between patients with and without progression using the Wilcoxon signed-rank test. Any measure significantly associated with two-year TTP was added to an existing logistic regression model based on baseline tumour characteristics to assess its added prognostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with progression showed a significantly higher spleen-to-blood SUVmean ratio, lower SUVmean and TLG in the brain, lower SUVmean in skeletal muscle, and a larger liver volume. Liver volume and spleen-to-blood SUVmean ratio did not significantly improve the prediction of two-year TTP compared to the original model only based on tumour characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Healthy tissue PET\/CT measures were significantly associated with two-year TTP in DLBCL patients. However, these measures did not improve the prediction of two-year TTP compared to models using only tumour characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number and date of registration<\/jats:title>\n                    <jats:p>HOVON-84: EudraCT: 2006-005, 174\u2009\u2212\u200942, retrospectively registered 01-08-2008.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07503-9","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T05:17:59Z","timestamp":1755494279000},"page":"1053-1063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can we obtain prognostic information from healthy tissue uptake and volume in baseline 18F-FDG PET\/CT imaging in diffuse large B-cell lymphoma?"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7288-7416","authenticated-orcid":false,"given":"Nienke R.","family":"Gerards","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-8121","authenticated-orcid":false,"given":"Sanne E.","family":"Wiegers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne L.","family":"Bes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-0016","authenticated-orcid":false,"given":"Jakoba J.","family":"Eertink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-8651","authenticated-orcid":false,"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1074-5922","authenticated-orcid":false,"given":"Jos\u00e9e M.","family":"Zijlstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0313-5686","authenticated-orcid":false,"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9571-9362","authenticated-orcid":false,"given":"Gerben J.C.","family":"Zwezerijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"Suppl 1","key":"7503_CR1","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.2967\/jnumed.108.057190","volume":"50","author":"M Hutchings","year":"2009","unstructured":"Hutchings M, Barrington SF. PET\/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50(Suppl 1):S21\u201330. https:\/\/doi.org\/10.2967\/jnumed.108.057190.","journal-title":"J Nucl Med"},{"key":"7503_CR2","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/annonc\/mdp531","volume":"21","author":"A Bari","year":"2010","unstructured":"Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol. 2010;21:1486\u201391. https:\/\/doi.org\/10.1093\/annonc\/mdp531.","journal-title":"Ann Oncol"},{"key":"7503_CR3","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","volume":"41","author":"M Sasanelli","year":"2014","unstructured":"Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017\u201322. https:\/\/doi.org\/10.1007\/s00259-014-2822-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7503_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00259-019-04309-4","volume":"46","author":"QA Shagera","year":"2019","unstructured":"Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS, et al. Prognostic value of metabolic tumour volume on baseline 18F-FDG PET\/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging. 2019;46:1417\u201327. https:\/\/doi.org\/10.1007\/s00259-019-04309-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7503_CR5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, Moller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209\u201319. https:\/\/doi.org\/10.1007\/s00259-016-3315-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7503_CR6","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.2967\/jnumed.124.268191","volume":"65","author":"MC Ferrandez","year":"2024","unstructured":"Ferrandez MC, Golla SSV, Eertink JJ, Wiegers SE, Zwezerijnen GJC, Heymans MW, et al. Validation of an artificial Intelligence-Based prediction model using 5 external PET\/CT datasets of diffuse large B-Cell lymphoma. J Nucl Med. 2024;65:1802\u20137. https:\/\/doi.org\/10.2967\/jnumed.124.268191.","journal-title":"J Nucl Med"},{"key":"7503_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06409-8","author":"F Ge","year":"2025","unstructured":"Ge F, Wu T, Yang X, Peng M, Yang C, Wang K. Feasibility analysis of metabolic parameters based on baseline 18F-FDG PET\/CT to predict heterogeneity and recurrence of diffuse large B-cell lymphoma. Ann Hematol. 2025. https:\/\/doi.org\/10.1007\/s00277-025-06409-8.","journal-title":"Ann Hematol"},{"key":"7503_CR8","doi-asserted-by":"publisher","first-page":"754964","DOI":"10.3389\/fonc.2021.754964","volume":"11","author":"X Shi","year":"2021","unstructured":"Shi X, Liu X, Li X, Li Y, Lu D, Sun X, et al. Risk stratification for diffuse large B-Cell lymphoma by integrating interim evaluation and international prognostic index: A multicenter retrospective study. Front Oncol. 2021;11:754964. https:\/\/doi.org\/10.3389\/fonc.2021.754964.","journal-title":"Front Oncol"},{"key":"7503_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00330-022-09031-8","volume":"33","author":"C Yuan","year":"2023","unstructured":"Yuan C, Shi Q, Huang X, Wang L, He Y, Li B, et al. Multimodal deep learning model on interim 18F-FDG PET\/CT for predicting primary treatment failure in diffuse large B-cell lymphoma. Eur Radiol. 2023;33:77\u201388. https:\/\/doi.org\/10.1007\/s00330-022-09031-8.","journal-title":"Eur Radiol"},{"key":"7503_CR10","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1007\/s00259-023-06405-y","volume":"50","author":"C Jiang","year":"2023","unstructured":"Jiang C, Qian C, Jiang Z, Teng Y, Lai R, Sun Y, et al. Robust deep learning-based PET prognostic imaging biomarker for DLBCL patients: a multicenter study. Eur J Nucl Med Mol Imaging. 2023;50:3949\u201360. https:\/\/doi.org\/10.1007\/s00259-023-06405-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7503_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.crad.2023.01.010","volume":"78","author":"S Wang","year":"2023","unstructured":"Wang S, Ju H, Bai Y, Wang L, Ding Q, Li P, et al. The prognostic value of Splenic abnormalities in pretreatment 18F-FDG PET\/CT in patients with complete response diffuse large B-cell lymphoma. Clin Radiol. 2023;78:375\u201380. https:\/\/doi.org\/10.1016\/j.crad.2023.01.010.","journal-title":"Clin Radiol"},{"key":"7503_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40644-020-00313-2","volume":"20","author":"A Wong","year":"2020","unstructured":"Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, et al. 18F-FDG PET\/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging. 2020;20:36. https:\/\/doi.org\/10.1186\/s40644-020-00313-2.","journal-title":"Cancer Imaging"},{"key":"7503_CR13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/s41598-018-35912-4","volume":"9","author":"SY Kim","year":"2019","unstructured":"Kim SY, Moon CM, Yoon HJ, Kim BS, Lim JY, Kim TO, et al. Diffuse Splenic FDG uptake is predictive of clinical outcomes in patients with rectal cancer. Sci Rep. 2019;9:1313. https:\/\/doi.org\/10.1038\/s41598-018-35912-4.","journal-title":"Sci Rep"},{"key":"7503_CR14","doi-asserted-by":"publisher","first-page":"e28791","DOI":"10.1097\/MD.0000000000028791","volume":"101","author":"F Godard","year":"2022","unstructured":"Godard F, Durot E, Durot C, Hoeffel C, Delmer A, Morland D. Cerebellum\/liver index in pretherapeutic 18F-FDG PET\/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenance. Med (Baltim). 2022;101:e28791. https:\/\/doi.org\/10.1097\/MD.0000000000028791.","journal-title":"Med (Baltim)"},{"key":"7503_CR15","doi-asserted-by":"publisher","first-page":"913866","DOI":"10.3389\/fmed.2022.913866","volume":"9","author":"D Morland","year":"2022","unstructured":"Morland D, Triumbari EKA, Maiolo E, Cuccaro A, Treglia G, Hohaus S, et al. Healthy organs uptake on baseline 18F-FDG PET\/CT as an alternative to total metabolic tumor volume to predict Event-Free survival in classical hodgkin\u2019s lymphoma. Front Med (Lausanne). 2022;9:913866. https:\/\/doi.org\/10.3389\/fmed.2022.913866.","journal-title":"Front Med (Lausanne)"},{"key":"7503_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s12149-021-01609-4","volume":"35","author":"D Morland","year":"2021","unstructured":"Morland D, Zizi G, Godard F, Gauchy AC, Durot C, Hoeffel C, et al. 18F-FDG cerebellum\/liver index as a prognostic factor for progression-free survival in diffuse large B-cell lymphoma. Ann Nucl Med. 2021;35:785\u201393. https:\/\/doi.org\/10.1007\/s12149-021-01609-4.","journal-title":"Ann Nucl Med"},{"key":"7503_CR17","doi-asserted-by":"publisher","first-page":"12613","DOI":"10.1038\/s41598-024-63349-5","volume":"14","author":"AA Malaih","year":"2024","unstructured":"Malaih AA, Kirkwood AA, Johnson P, Radhakrishnan V, Fischer BM, Barrington SF. Healthy tissue metabolism assessed by 18F-FDG PET\/CT as a marker of prognosis and adverse events in advanced hodgkin lymphoma patients. Sci Rep. 2024;14:12613. https:\/\/doi.org\/10.1038\/s41598-024-63349-5.","journal-title":"Sci Rep"},{"key":"7503_CR18","doi-asserted-by":"publisher","first-page":"620696","DOI":"10.3389\/fnut.2021.620696","volume":"8","author":"G Besutti","year":"2021","unstructured":"Besutti G, Massaro F, Bonelli E, Braglia L, Casali M, Versari A, et al. Prognostic impact of muscle quantity and quality and fat distribution in diffuse large B-Cell lymphoma patients. Front Nutr. 2021;8:620696. https:\/\/doi.org\/10.3389\/fnut.2021.620696.","journal-title":"Front Nutr"},{"key":"7503_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3109\/10428194.2013.816421","volume":"55","author":"H Lanic","year":"2014","unstructured":"Lanic H, Kraut-Tauzia J, Modzelewski R, Clatot F, Mareschal S, Picquenot JM, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma. 2014;55:817\u201323. https:\/\/doi.org\/10.3109\/10428194.2013.816421.","journal-title":"Leuk Lymphoma"},{"key":"7503_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.119.229450","volume":"61","author":"AS Cottereau","year":"2020","unstructured":"Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, et al. 18F-FDG PET dissemination features in diffuse large B-Cell lymphoma are predictive of outcome. J Nucl Med. 2020;61:40\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.229450.","journal-title":"J Nucl Med"},{"key":"7503_CR21","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2967\/jnumed.121.263501","volume":"63","author":"KB Girum","year":"2022","unstructured":"Girum KB, Rebaud L, Cottereau AS, Meignan M, Clerc J, Vercellino L, et al. 18F-FDG PET Maximum-Intensity projections and artificial intelligence: A Win-Win combination to easily measure prognostic biomarkers in DLBCL patients. J Nucl Med. 2022;63:1925\u201332. https:\/\/doi.org\/10.2967\/jnumed.121.263501.","journal-title":"J Nucl Med"},{"key":"7503_CR22","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.03418","volume":"38","author":"PJ Lugtenburg","year":"2020","unstructured":"Lugtenburg PJ, de Nully Brown P, van der Holt B, D\u2019Amore FA, Koene HR, de Jongh E, et al. Rituximab-CHOP with early rituximab intensification for diffuse large B-Cell lymphoma: A randomized phase III trial of the HOVON and the nordic lymphoma group (HOVON-84). J Clin Oncol. 2020;38:3377\u201387. https:\/\/doi.org\/10.1200\/JCO.19.03418.","journal-title":"J Clin Oncol"},{"key":"7503_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7503_CR24","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s00259-021-05480-3","volume":"49","author":"JJ Eertink","year":"2022","unstructured":"Eertink JJ, van de Brug T, Wiegers SE, Zwezerijnen GJC, Pfaehler EAG, Lugtenburg PJ, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022;49:932\u201342. https:\/\/doi.org\/10.1007\/s00259-021-05480-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7503_CR25","doi-asserted-by":"publisher","first-page":"e230024","DOI":"10.1148\/ryai.230024","volume":"5","author":"J Wasserthal","year":"2023","unstructured":"Wasserthal J, Breit HC, Meyer MT, Pradella M, Hinck D, Sauter AW, et al. TotalSegmentator: robust segmentation of 104 anatomic structures in CT images. Radiol Artif Intell. 2023;5:e230024. https:\/\/doi.org\/10.1148\/ryai.230024.","journal-title":"Radiol Artif Intell"},{"key":"7503_CR26","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s11307-020-01474-z","volume":"22","author":"CN Burggraaff","year":"2020","unstructured":"Burggraaff CN, Rahman F, Kassner I, Pieplenbosch S, Barrington SF, Jauw YWS, et al. Optimizing workflows for fast and reliable metabolic tumor volume measurements in diffuse large B cell lymphoma. Mol Imaging Biol. 2020;22:1102\u201310. https:\/\/doi.org\/10.1007\/s11307-020-01474-z.","journal-title":"Mol Imaging Biol"},{"key":"7503_CR27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2967\/jnumed.119.238923","volume":"62","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Zwezerijnen B, de Vet HCW, Heymans MW, Mikhaeel NG, Burggraaff CN, et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-Cell lymphoma: which method is most successful?? A study on behalf of the PETRA consortium. J Nucl Med. 2021;62:332\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.238923.","journal-title":"J Nucl Med"},{"key":"7503_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345.","journal-title":"Biometrics"},{"key":"7503_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1259\/bjr\/31542964","volume":"85","author":"SS Saboo","year":"2012","unstructured":"Saboo SS, Krajewski KM, O\u2019Regan KN, Giardino A, Brown JR, Ramaiya N, et al. Spleen in haematological malignancies: spectrum of imaging findings. Br J Radiol. 2012;85:81\u201392. https:\/\/doi.org\/10.1259\/bjr\/31542964.","journal-title":"Br J Radiol"},{"key":"7503_CR30","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"key":"7503_CR31","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/MNM.0b013e32832fa254","volume":"30","author":"Y Liu","year":"2009","unstructured":"Liu Y. Clinical significance of diffusely increased Splenic uptake on FDG-PET. Nucl Med Commun. 2009;30:763\u20139. https:\/\/doi.org\/10.1097\/MNM.0b013e32832fa254.","journal-title":"Nucl Med Commun"},{"key":"7503_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Ho AD, Covallin-Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera international trial group (MInT) study. Lancet Oncol. 2008;9:435\u201344. https:\/\/doi.org\/10.1016\/S1470-2045(08)70078-0.","journal-title":"Lancet Oncol"},{"key":"7503_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12149-010-0415-5","volume":"24","author":"K Hanaoka","year":"2010","unstructured":"Hanaoka K, Hosono M, Shimono T, Usami K, Komeya Y, Tsuchiya N, et al. Decreased brain FDG uptake in patients with extensive non-Hodgkin\u2019s lymphoma lesions. Ann Nucl Med. 2010;24:707\u201311. https:\/\/doi.org\/10.1007\/s12149-010-0415-5.","journal-title":"Ann Nucl Med"},{"key":"7503_CR34","first-page":"784","volume":"45","author":"N Paquet","year":"2004","unstructured":"Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of 18F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784\u20138.","journal-title":"J Nucl Med"},{"key":"7503_CR35","doi-asserted-by":"publisher","first-page":"11557","DOI":"10.1038\/s41598-018-29937-y","volume":"8","author":"K Ishibashi","year":"2018","unstructured":"Ishibashi K, Onishi A, Fujiwara Y, Oda K, Ishiwata K, Ishii K. Longitudinal effects of aging on 18F-FDG distribution in cognitively normal elderly individuals. Sci Rep. 2018;8:11557. https:\/\/doi.org\/10.1038\/s41598-018-29937-y.","journal-title":"Sci Rep"},{"key":"7503_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cpet.2013.10.006","volume":"9","author":"V Berti","year":"2014","unstructured":"Berti V, Mosconi L, Pupi A. Brain: normal variations and benign findings in fluorodeoxyglucose-PET\/computed tomography imaging. PET Clin. 2014;9:129\u201340. https:\/\/doi.org\/10.1016\/j.cpet.2013.10.006.","journal-title":"PET Clin"},{"key":"7503_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11604-024-01672-7","volume":"43","author":"R Minamimoto","year":"2025","unstructured":"Minamimoto R, Kato K, Naganawa S. Clinical scenarios of unusual FDG uptake in muscle. Jpn J Radiol. 2025;43:177\u201385. https:\/\/doi.org\/10.1007\/s11604-024-01672-7.","journal-title":"Jpn J Radiol"},{"key":"7503_CR38","doi-asserted-by":"publisher","first-page":"e47903","DOI":"10.15252\/embr.201947903","volume":"20","author":"J Castillo-Armengol","year":"2019","unstructured":"Castillo-Armengol J, Fajas L, Lopez-Mejia IC. Inter-organ communication: a gatekeeper for metabolic health. EMBO Rep. 2019;20:e47903. https:\/\/doi.org\/10.15252\/embr.201947903.","journal-title":"EMBO Rep"},{"key":"7503_CR39","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1007\/s00259-022-05832-7","volume":"49","author":"T Sun","year":"2022","unstructured":"Sun T, Wang Z, Wu Y, Gu F, Li X, Bai Y, et al. Identifying the individual metabolic abnormities from a systemic perspective using whole-body PET imaging. Eur J Nucl Med Mol Imaging. 2022;49:2994\u20133004. https:\/\/doi.org\/10.1007\/s00259-022-05832-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7503_CR40","doi-asserted-by":"publisher","first-page":"120030","DOI":"10.1016\/j.neuroimage.2023.120030","volume":"271","author":"MB Reed","year":"2023","unstructured":"Reed MB, Ponce de Leon M, Vraka C, Rausch I, Godbersen GM, Popper V, et al. Whole-body metabolic connectivity framework with functional PET. NeuroImage. 2023;271:120030. https:\/\/doi.org\/10.1016\/j.neuroimage.2023.120030.","journal-title":"NeuroImage"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07503-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07503-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07503-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:46:32Z","timestamp":1769222792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07503-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7503"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07503-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The HOVON-84 study was approved by the institutional review board of the Erasmus MC (2007-055) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later versions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the HOVON-84 study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Pieternella Lugtenburg received financial support for clinical trials from Takeda and Roche. Jos\u00e9e Zijlstra received financial support for clinical trials from Roche, Gilead, and Takeda. Ronald Boellaard is scientific advisor of the EARL PET\/CT accreditation programme. No other potential conflict of interest relevant to this article was reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}